Not logged in
  Home   Markets   Shares   Funds   Portfolio   Toolbox   Charting   Alerts   Directory   
 Admin   

Tue 31 Aug 2004, 16:41 Agreement regarding Lazaron Biotechnologies
JDH - Agreement regarding Lazaron Biotechnologies (SA) Ltd and Withdrawal of    
      Cautionary Announcement                                                   
John Daniel Holdings Limited                                                    
Registration number 1998/013215/06)                                             
SHARE CODE: JDH                                                                 
ISIN: ZAE000044343                                                              
(`JDH` or `the company`)                                                        
Agreement regarding Lazaron Biotechnologies (SA) Ltd and Withdrawal of          
Cautionary Announcement                                                         
LPC Manhattan Sponsors (Pty) Ltd is authorized to announce that further to the  
cautionary announcement dated 24 June 2004 regarding the acquisition of an      
interest in a bio-technology company referred to as `Bioco` and a further       
cautionary announcement dated 27 August 2004, JDH has reached an agreement for  
the acquisition of a 25% stake in Lazaron, a newly incorporated Biotechnology   
Company.  Lazaron has obtained the exclusive licence for the commercialization  
of all technologies emanating from research conducted in the field of animal and
human stem cell research from the biotechnology laboratories in the Department  
of Animal Sciences of the University of Stellenbosch.                           
The purchase consideration is settled at nominal share value.  JDH will also    
provide a short term loan in the amount of R2.5 million to Lazaron for the      
acquisition of a specialized stem cell sorter.                                  
Lazaron will shortly commence a private placement of shares to institutions and 
medical professionals, consequently it is envisaged that the JDH shareholding   
will dilute to around 15% in future.                                            
The board views the acquisition as a very strategic investment in line with the 
adopted Vision 2005 Business Strategy.                                          
Stakeholders are advised that they no longer need to exercise caution in dealing
in the company`s shares.  Lazaron has scheduled a press conference for 10H00 on 
Wednesday, 1 September 2004 at which time Lazaron will provide full details of  
its business strategy together with its advances in stem cell research at the   
cutting edge of medical sciences.                                               
Stellenbosch                                                                    
31 August 2004                                                                  
Sponsor                                                                         
LPC Manhattan Sponsors (Pty) Ltd                                                
(Registration number 1999/024792/07)                                            
Date: 31/08/2004 04:25:03 PM                   
Produced by the JSE SENS Department
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
Other Profile Group sites: FundsData Online (unit trust data)  |  Profile Group corporate site
[  Terms of Use |  Privacy Policy |  PAIA manual |  FAQs/Help |  Site Map |  © Copyright Reserved 2026  ]
  


Powered by ProfileData

Profile Mobile App Google Play Store Apple App Store


Follow us on: